BIO Critiques CMS' Justification Of ASP+4% For Hospital Outpatient Drugs
Executive Summary
The Biotechnology Industry Organization is maintaining its stance that if Medicare pays anything less than average sales price plus 6 percent for drugs and biologics in the hospital outpatient setting, hospital pharmacies will be under-reimbursed